Horizon Therapeutics plc: Newly Published Data Continue to Support Long-Term Efficacy of TEPEZZA (teprotumumab-trbw) for Thyroid Eye Disease (TED)

-- Comprehensive OPTIC-X trial results published in Ophthalmology, including new long-term follow-up data Horizon Therapeutics plc (Nasdaq: HZNP) today announced additional data supporting the long-term

Related Keywords

United States ,Ireland ,Michigan ,American ,Jeffreyw Sherman ,Ruth Venning ,Tina Ventura ,Terryj Smith ,Ray Gordon ,Rachel Vann ,Instagram ,Product Communications ,Linkedin ,Meeting Of The American Thyroid Association ,Twitter ,Kellogg Eye Center ,Visa ,Drug Administration ,Nasdaq ,Exchange Commission ,European Group On Grave Orbitopathy ,University Of Michigan Medical School ,Facebook ,Clinical Activity Score ,Thyroid Eye Disease ,Eye Disease ,Annual Meeting ,American Thyroid Association ,Michigan Medicine Eye Plastic ,Facial Cosmetic Orbital Surgery ,Michigan Medical School ,Thyroid Eye ,Inflammatory Bowel Disease ,Full Prescribing Information ,United States Securities ,Thyroid Associated ,Grave Disease Is Mediated Through ,Insulin Like Growth Factor ,Grave Orbitopathy ,Clinical Practice Guidelines ,Medical Management ,European Group ,Vice President ,Investor Relations ,Horizon ,Herapeutics ,Ewly ,Published ,Data ,Ontinue ,Support ,Song ,Term ,Efficacy ,Tepezza ,Teprotumumab ,Brbw ,Thyroid ,Disease ,